{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T15:27:55Z","timestamp":1790954875477,"version":"4.1.0"},"reference-count":32,"publisher":"SAGE Publications","issue":"3","license":[{"start":{"date-parts":[[2025,12,2]],"date-time":"2025-12-02T00:00:00Z","timestamp":1764633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Psychopharmacol"],"published-print":{"date-parts":[[2026,3]]},"abstract":"<jats:p>This systematic review explores the role of the endocannabinoid system (ECS) in prodromal psychosis and its potential as a therapeutic target. Following Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines, 22 studies published between 2000 and 2025 were analyzed, comprising preclinical research, genetic studies, neuroimaging investigations, and clinical trials. Converging evidence suggests that ECS alterations precede and potentially contribute to the development of psychotic symptoms, with CB1 receptor modifications and endocannabinoid levels correlating with symptom severity and transition risk to full-blown psychosis. Neuroimaging studies revealed reduced CB1 receptor availability in key brain regions in high-risk subjects, and intervention studies, particularly with cannabidiol\u2014though its therapeutic mechanisms likely extend beyond ECS modulation to include dopaminergic and other neurotransmitter pathways\u2014have shown promising results. Proposed mechanisms of action include stress response attenuation, neuroinflammatory modulation, neurodevelopmental stabilization, and normalization of the dopamine-glutamate interface. Despite limitations of existing studies, primarily small size and short duration, this review provides a solid foundation for developing ECS-targeted interventions as a promising approach to modify disease trajectory during the prodromal phase, potentially offering safer and more effective therapeutic options for individuals at clinical high risk for psychosis.<\/jats:p>","DOI":"10.1177\/02698811251389574","type":"journal-article","created":{"date-parts":[[2025,12,2]],"date-time":"2025-12-02T10:00:32Z","timestamp":1764669632000},"page":"351-368","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":2,"title":["The endocannabinoid system as a therapeutic target in prodromal psychosis: From molecular mechanisms to clinical applications"],"prefix":"10.1177","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1717-2530","authenticated-orcid":false,"given":"Valerio","family":"Ricci","sequence":"first","affiliation":[{"name":"San Luigi Gonzaga Hospital, University of Turin, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Sarni","sequence":"additional","affiliation":[{"name":"San Luigi Gonzaga Hospital, University of Turin, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Domenico","family":"De Berardis","sequence":"additional","affiliation":[{"name":"Department of Mental Health, Psychiatric Service for Diagnosis and Treatment, Hospital \u201cG. Mazzini,\u201d Teramo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7292-2341","authenticated-orcid":false,"given":"Giovanni","family":"Martinotti","sequence":"additional","affiliation":[{"name":"Department of Neurosciences, Imaging and Clinical Sciences, Universit\u00e0 degli Studi G. D\u2019Annunzio \u2013 Chieti-Pescara, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Maina","sequence":"additional","affiliation":[{"name":"San Luigi Gonzaga Hospital, University of Turin, Italy"},{"name":"Department of Neurosciences \u201cRita Levi Montalcini,\u201d University of Turin, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2025,12,2]]},"reference":[{"key":"e_1_3_3_2_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-019-05442-6"},{"key":"e_1_3_3_3_1","doi-asserted-by":"publisher","DOI":"10.1017\/S0033291719001946"},{"key":"e_1_3_3_4_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.npp.1301344"},{"key":"e_1_3_3_5_1","doi-asserted-by":"publisher","DOI":"10.1038\/npp.2009.184"},{"key":"e_1_3_3_6_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2018.2309"},{"key":"e_1_3_3_7_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2019.1427"},{"key":"e_1_3_3_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neubiorev.2018.07.014"},{"key":"e_1_3_3_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2215-0366(18)30427-9"},{"key":"e_1_3_3_10_1","doi-asserted-by":"publisher","DOI":"10.1002\/wps.20526"},{"key":"e_1_3_3_11_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41398-020-0862-2"},{"key":"e_1_3_3_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopsych.2012.06.020"},{"key":"e_1_3_3_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2215-0366(19)30048-3"},{"key":"e_1_3_3_14_1","doi-asserted-by":"crossref","unstructured":"Di Marzo V Bifulco M De Petrocellis L (2004) The endocannabinoid system and its therapeutic exploitation. Nature Reviews. Drug Discovery 3(9): 771\u2013784. https:\/\/doi.org\/10.1038\/nrd1495","DOI":"10.1038\/nrd1495"},{"key":"e_1_3_3_15_1","article-title":"The endocannabinoid system and its role in schizophrenia: A systematic review of the literature","volume":"34","author":"Ferretjans R","year":"2012","unstructured":"Ferretjans R, Moreira FA, Teixeira AL, et al. (2012) The endocannabinoid system and its role in schizophrenia: A systematic review of the literature. Revista brasileira de psiquiatria (Sao Paulo, Brazil : 1999) 34(Suppl. 2): S163\u2013S177.","journal-title":"Revista brasileira de psiquiatria (Sao Paulo, Brazil : 1999)"},{"key":"e_1_3_3_16_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2013.269"},{"key":"e_1_3_3_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2015.01.015"},{"key":"e_1_3_3_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopsych.2007.12.005"},{"key":"e_1_3_3_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/ejn.15509"},{"issue":"4","key":"e_1_3_3_20_1","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1192\/bjp.bp.108.053843","article-title":"Anandamide elevation in cerebrospinal fluid in initial prodromal states of psychosis","volume":"194","author":"Koethe D","year":"2009","unstructured":"Koethe D, Giuffrida A, Schreiber D, et al. (2009) Anandamide elevation in cerebrospinal fluid in initial prodromal states of psychosis. The British Journal of Psychiatry: The Journal of Mental Science 194(4): 371\u2013372.","journal-title":"The British Journal of Psychiatry: The Journal of Mental Science"},{"key":"e_1_3_3_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2007.04.025"},{"key":"e_1_3_3_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopsych.2015.07.028"},{"key":"e_1_3_3_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.psychres.2017.01.045"},{"key":"e_1_3_3_24_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41380-018-0215-1"},{"key":"e_1_3_3_25_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2017.17030325"},{"key":"e_1_3_3_26_1","doi-asserted-by":"publisher","DOI":"10.1017\/S0033291719003519"},{"key":"e_1_3_3_27_1","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.64.1.19"},{"key":"e_1_3_3_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopsych.2015.08.021"},{"key":"e_1_3_3_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbi.2023.02.002"},{"key":"e_1_3_3_30_1","doi-asserted-by":"publisher","DOI":"10.1038\/tp.2016.195"},{"key":"e_1_3_3_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2020.114004"},{"key":"e_1_3_3_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pscychresns.2015.05.005"},{"key":"e_1_3_3_33_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41386-018-0282-7"}],"container-title":["Journal of Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/02698811251389574","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/02698811251389574","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/02698811251389574","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T11:24:31Z","timestamp":1781004271000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/02698811251389574"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,2]]},"references-count":32,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["10.1177\/02698811251389574"],"URL":"https:\/\/doi.org\/10.1177\/02698811251389574","relation":{},"ISSN":["0269-8811","1461-7285"],"issn-type":[{"value":"0269-8811","type":"print"},{"value":"1461-7285","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,2]]}}}